▶ TRI-RECEPTOR INCRETIN AGONIST · SUBTOPIC · MECHANISM
TRI-RECEPTOR INCRETIN AGONIST Mechanism
For Laboratory Research Use Only. The mechanistic information below is descriptive of published research. No human dose is recommended. No clinical claim is made.
MECHANISM OF ACTION
Engineered single-molecule agonist at GLP-1, GIP, and glucagon receptors. Investigational compound from the originator pharma sponsor under its development codename.
PHARMACOKINETIC HALF-LIFE
Reported half-life for TRI-RECEPTOR INCRETIN AGONIST: ~6 days. Half-life determines the kinetic window across which receptor occupancy is maintained and frames the dosing rhythm used in published literature.
MECHANISM CATEGORIES
TRI-RECEPTOR INCRETIN AGONIST is tagged in 2 mechanism categories on GIGARESEARCH. Each category aggregates the broader pharmacology of related compounds.
The incretin axis encompasses GLP-1 (glucagon-like peptide 1) and GIP (glucose-dependent insulinotropic polypeptide), gut hormones released in response to nutrient intake that account for roughly 70% of postprandial insulin secretion. Drugs targeting this axis include single GLP-1 agonists (the long-acting GLP-1 agonist), dual GLP-1/GIP agonists (the GLP-1 / GIP dual agonist), and triple GLP-1/GIP/glucagon agonists (the triple-receptor incretin agonist). The axis is the largest commercial pharma category of the 2020s and is responsible for the metabolic-medicine revolution underway in obesity, type 2 diabetes, and cardiometabolic disease.
Compounds acting on metabolic regulation include incretin agonists (GLP-1, GIP, glucagon), AMPK activators (MOTS-c), and GHRH analogs that drive lipolysis (tesamorelin). The shared therapeutic target is metabolic dysfunction underlying obesity, type 2 diabetes, NAFLD, and the broader cardiometabolic syndrome.
MECHANISTIC OUTCOMES IN LITERATURE
The following outcomes are the mechanistic endpoints reported in the peer-reviewed literature, with GIGARESEARCH evidence grades. Grades reflect study quality and replication, not clinical recommendation.
Phase 2 NEJM 2023 reported dose-dependent -7.2% to -17.5% LS mean change at 24w (Jastreboff et al., PMID 37366315). High-quality RCT.
Same trial 48-week extension: -8.7% to -24.2% LS mean. n=338.
Glycemic endpoints improved despite GCGR engagement. Phase 3 TRIUMPH data pending.
Phase 2 GI tolerability profile dose-dependent; dose-related heart-rate increases noted. Phase 3 ongoing.
MECHANISM Q+A
▶ What is the triple-receptor incretin agonist?
the triple-receptor incretin agonist (the originator pharma sponsor code its development codename) is a synthetic peptide engineered as a triple agonist at the GLP-1, GIP, and glucagon receptors. It is an investigational compound · not FDA-approved · currently in the Phase 3 TRIUMPH program.
▶ How does the triple-receptor incretin agonist differ from the GLP-1 / GIP dual agonist?
the GLP-1 / GIP dual agonist is a dual GLP-1R + GIPR agonist. the triple-receptor incretin agonist adds glucagon-receptor agonism on top, which is the key pharmacological differentiator and the basis for the deeper observed weight reductions in Phase 2.
▶ Is the triple-receptor incretin agonist FDA-approved?
No. the triple-receptor incretin agonist is an investigational compound. The Phase 3 TRIUMPH program is ongoing. The substance sold here is supplied as a research-grade reference compound for in-vitro use only.
▶ What is the half-life of the triple-receptor incretin agonist?
Published pharmacokinetic data indicate a terminal half-life around six days, consistent with once-weekly dosing in trials.
▶ Is the triple-receptor incretin agonist banned by WADA?
the triple-receptor incretin agonist is not currently listed on the WADA Prohibited List as of the 2026 update. Status can change · always verify with the current WADA list before competition.
▶ Can the triple-receptor incretin agonist be stacked with the GLP-1 / GIP dual agonist?
No published research supports simultaneous use of multiple incretin agonists. They engage overlapping pathways and combined use is unstudied. This wiki does not recommend any human dose or combination.
▶ Why does the triple-receptor incretin agonist cause more weight loss than the GLP-1 / GIP dual agonist in trials?
The hypothesis is that glucagon-receptor agonism adds a thermogenic / increased-energy-expenditure component on top of the GLP-1R/GIPR appetite-and-insulin effects. Mechanism is under active study.
▶ What is the manufacturer of the triple-receptor incretin agonist?
The originator molecule is property of the originator pharma sponsor under the development code its development codename. Research-grade compounds supplied through GigaCompounds are synthesized for laboratory use only and are distinct from any branded human-prescription formulation.
▶ How long do the triple-receptor incretin agonist cycles last in published trials?
The published Phase 2 trial dosed once-weekly for 48 weeks. Phase 3 TRIUMPH durations vary by sub-study; consult ClinicalTrials.gov for current protocols.
▶ Does the triple-receptor incretin agonist affect heart rate?
Phase 2 reported dose-dependent increases in resting heart rate peaking around 24 weeks before declining. This is a class-level signal for incretin agonists at higher doses.
▶ Is the triple-receptor incretin agonist oral or injectable in trials?
Published trials use subcutaneous injection only. There is no approved or studied oral formulation as of the Phase 2 publication.
▶ What does triple receptor agonism mean?
the triple-receptor incretin agonist engages three receptors simultaneously: GLP-1R, GIPR, and the glucagon receptor (GCGR). Each receptor drives a distinct branch of metabolic and energy-expenditure signaling; the molecule is engineered to balance all three.
▶ the triple-receptor incretin agonist vs the FDA-approved class member / the long-acting GLP-1 agonist · what's different?
the long-acting GLP-1 agonist (the FDA-approved class member, the FDA-approved class member) is a GLP-1 receptor agonist only. the triple-receptor incretin agonist is a triple agonist at GLP-1, GIP and the glucagon receptor. The added GIP arm increases absolute weight loss over the long-acting GLP-1 agonist at comparable timepoints. The added glucagon arm drives thermogenic / energy-expenditure signaling that the long-acting GLP-1 agonist does not produce. Published Phase 2 the triple-receptor incretin agonist reached -24.2% body weight at 48 weeks vs the published STEP-1 the long-acting GLP-1 agonist 2.4 mg result of -14.9% at 68 weeks.
CITED LITERATURE
- Jastreboff AM, Kaplan LM, Frías JP, et al.. Triple-Hormone-Receptor Agonist the triple-receptor incretin agonist for Obesity · A Phase 2 Trial. N Engl J Med 2023. PMID 37366315. link
- the originator pharma sponsor and Company. A Study of its development codename in Participants With Obesity (Phase 2). ClinicalTrials.gov 2021. NCT04881760. link
RELATED PAGES
▶ LAST UPDATED · 2026-05-19